McKesson (MCK) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

McKesson

NYSE•Healthcare•Medical Distribution

$879.57-7.72(-0.01%)After hours

Market Cap

$105.32B

P/E

22.9x

P/S

0.3x

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

How this company scores

WeakMetricSide Score: 53/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (21/25); weakest: Profitability (3/25).

Profitability3/25

Growth21/25

Balance Sheet & Red Flags9/25

Cash & Earnings Quality20/25

Strengths

Rising earningsCash-backed earningsConsistent growthNo share dilution

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 22.9x5y range 13.8x – 40.6x

Currently near its 19-quarter median.

P/S · 0.3x5y range 0.1x – 0.3x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Cash Burn

Watch

FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $105.32B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $410.98B
Q. Revenue: $105.38B
TTM EBITDA: $7.26B
TTM Op. Income: $6.50B
Q. Op. Income: $1.32B
TTM Net Income: $4.59B
Q. Net Income: $614.00M
EPS: $5.17
Shares Out.: $118.70M

$410.98B in TTM revenue grew 8.8% YoY, reaching $105.38B last quarter. TTM EBITDA of $7.26B and TTM operating income of $6.50B show growth is flowing through to the bottom line. TTM net income of $4.59B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 3.5%
EBITDA Margin: 1.4%
Op. Margin: 1.3%
Net Margin: 0.6%

Op. margin of 1.3% is up 0.2% YoY — cost efficiency is improving. Net margin at 0.6% and gross margin of 3.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 18% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 22.9x
P/S Ratio: 0.3x
P/B Ratio: N/A

At 22.9x P/E, the stock trades within typical market levels. P/S of 0.3x and P/B of 0.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 21% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $88.33B
Cash: $5.16B
Long-Term Debt: $9.73B
Book Value: $-4.24B
D/E Ratio: N/A
Debt/EBITDA: 6.4

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-220.00M
TTM Free Cash Flow: $6.42B
FCF Margin: 1.6%
FCF / Net Income: 1.4

TTM FCF of $6.42B on $-220.00M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 7% — an improving trend.